- Revelation Biosciences Inc. closed a private placement financing, raising gross proceeds of $4.4m
- The company sold 684,444 shares of Series A-1 Preferred Stock at a purchase price of $6.36 per share
- The company also intends to use the net proceeds of the offering for general working capital purposes and the development of REVTx-99 and REVDx-50
- REVTx-99 being developed as a therapy for the treatment of a wide range of respiratory viral infections, including COVID-19
- REVDx-501 is a diagnostic being developed to test for upper respiratory viral infections including COVID-19
- The funding will also facilitate investigation into potential additional indications for REVTx-99, and general and administrative operations
